All News

switch.jpg

Swapping is Better than Cycling in Psoriatic Arthritis

Jack Cush, MD

A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.

Read Article
RheumNow Podcast square

Blue Collar Arthritis (10.25.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

Systemic Sclerosis Insights (9.13.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
RF.jpg

Does Rheumatoid Factor Influence Anti-TNF Responses in RA?

Jack Cush, MD

Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated with adalimumab had a blunted response in the face of high RF titers.

Read Article
iritis-uveitis-e1333867439592.jpg

Immunomodulatory Prevention of Uveitis Relapse in Behçet's

Jack Cush, MD

The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease.

Read Article
Pain Relief in RA: JAK Better than TNF Inhibitors? Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest. https://t.co/olXQMGm2h8 https://t.co/Em7ydT33Ui

Links:

Dr. John Cush RheumNow ( View Tweet)
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today! https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologic (bio-originators) & biosimilar serious Infx rates are low & similar. Retro Study w/ 2+ yrs F/U shows hosp. Infx to be 7% infliximab & 2% etanercept. Similar SIE w/ ETA IR = 11.8 (7.9, 16.8) vs 8.4 (6.9, 10.1) & INFLX SIE IR= 33.4 (27.2, 40.1) vs 29.3 (26.6,… https://t.co/i2rP88ofEP https://t.co/XBW4tLC8YH
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 40 papers, 486,465 RA pts & 3,928 incident ILD outcomes shows no signif risk of ILD w/ DMARD use; no ILD risk w/ TOFA or TNFi (Oral Surveillance n=2,911; OR 0.94). MTX use yielded a Lower ILD risk (OR 0.49; 0.32 to 0.76) vs no MTX use. https://t.co/Es8yyEiD8r https://t.co/qOYPkWNi9o

Links:

Dr. John Cush RheumNow ( View Tweet)
Early bird registration for RheumNow Live is now open! Join us Feb 8-9 in Dallas, TX. Join the Revolution in Rheumatology Education! https://t.co/ygjZRMVkOZ

Links:

Dr. John Cush RheumNow ( View Tweet)

World renowned faculty delivering state of the art lectures. Early bird registration for RheumNow Live is now open! https://t.co/Yk8dKDdZie https://t.co/d14Mq2AxlI

Links:

Dr. John Cush RheumNow ( View Tweet)
Korean Claims analysis of 413 radiographic axial spondyloarthritis (TNFi exposed=75 ). Recurrent CV events = 32 per 1,000 person-years; but lower if TNFi Rx'd = 19/1000PYs. TNFi exposure significantly lowered risk of recurrent CV events https://t.co/f69SHpXZCx https://t.co/ofpg0JbrR1

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wvZYVbVW83 https://t.co/n26xAeU64s

Links:

Dr. John Cush RheumNow ( View Tweet)

CORRECTION!! UCB announced the LAUNCH of a new phase 3b BE BOLD trial - this study has no report results as yet. It WILL BE a H2H RCTcomparing bimekizumab & rizankizumab in adult #PsA pts using an ACR50 primary endpoint. Yesterday we incorrectly reported this as a completed… https://t.co/apa6VMuQTi https://t.co/BTpwo6ww7W

Dr. John Cush RheumNow ( View Tweet)
ACR 2024 Abstracts are available. Let the fun begin..... https://t.co/uNLZBqjEX0 Search by term, title or abstract # here: https://t.co/Du1eN4gA9D or Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG

Links:

Dr. John Cush RheumNow ( View Tweet)
Systemic Sclerosis Insights (9.13.2024) https://t.co/fRbKdSAqxG https://t.co/PMbYDXPHMd

Links:

Dr. John Cush RheumNow ( View Tweet)
Linger on the Fingers (9.6.2024) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. This week with a focus on fingers and better prescriptive follow through. https://t.co/c9yvRjE9av https://t.co/mdN37AWHjX

Links:

Dr. John Cush RheumNow ( View Tweet)
Claims analysis of two datasets showed TNFi treatment in 1st two years after newly Dx breast cancer (n 2216) had no effect on overall survival (OS); but had signif better breast cancer survival (HR 0.28; 0.08–0.98) vs csDMARD Rx. Pts on GC worse OS (HR 2.18)… https://t.co/Kxk7Sy7ahi https://t.co/PtxRsTifi1
Dr. John Cush RheumNow ( View Tweet)
Does Rheumatoid Factor Influence Anti-TNF Responses in RA? Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated… https://t.co/Ux9gHXcGbv https://t.co/gpcuWrqVHi
Dr. John Cush RheumNow ( View Tweet)
Claims analysis, shows <0.5% of IBD or RA pts developed an invasive fungal infx within 1 year of TNF therapy initiation (. Histoplasmosis was the most common IBD = 3.3 IFI/100PY RA = 2.8 IFF/100PY https://t.co/ER9YCxecJT https://t.co/T0UNgB4h6R

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×